Publication | Open Access

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

OncologyItalian NetworkMedicineMelanomaClinical TrialsImmune Checkpoint InhibitorPharmacotherapyAdvanced Melanoma PatientsMetronomic ChemotherapyCancer TreatmentPharmacologyTumor Biotherapy